enGene Therapeutics (ENGN) Current Leases (2024 - 2026)
enGene Therapeutics (ENGN) posted quarterly Current Leases of $2.3 million for Q2 2026, up 430.63% year-over-year from $431000.0 in Q2 2025, and down 1.34% quarter-over-quarter from $2.3 million in Q1 2026.
enGene Therapeutics (ENGN) Current Leases (2024 - 2026) Analysis & Trends
enGene Therapeutics (ENGN) has reported Current Leases for 3 consecutive years, with $2.3 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Current Leases rose 430.63% year-over-year to $2.3 million; the TTM figure through Apr 2026 stood at $2.3 million (up 430.63% YoY), while the FY2025 annual figure was $2.0 million, up 376.12% from the prior year.
- Current Leases declined to $2.3 million in Q2 2026 per ENGN's latest filing, from $2.3 million in the prior quarter.
- Across five years, Current Leases topped out at $2.3 million in Q1 2026 and bottomed at $393000.0 in Q1 2024.
- Historically, Current Leases has averaged $1.1 million across 3 years, with a median of $427000.0 in 2024.
- Annual changes were most pronounced in 2025 — Current Leases rose 2.38% — and 2026, when it surged 457.21%.
- enGene Therapeutics' Current Leases stood at $423000.0 in 2024, then surged by 376.12% to $2.0 million in 2025, then climbed by 13.56% to $2.3 million in 2026.
- Business Quant data shows ENGN's Current Leases at $2.3 million in Q2 2026, $2.3 million in Q1 2026, and $2.0 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.90 Bn | 132.05 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 86.70 Bn | 78.71 Bn | 3.93 Bn | 720.00 Mn |
| 3 | Argenx Se | 65.73 Bn | 60.55 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.33 Bn | 53.19 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 42.16 Bn | 37.07 Bn | 1.53 Bn | 21.95 Mn |
| 6 | Alnylam Pharmaceuticals | 31.72 Bn | 28.42 Bn | 992.69 Mn | 45.93 Mn |
| 7 | BioNTech SE | 28.27 Bn | 9.88 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.61 Bn | 26.45 Bn | 358.27 Mn | 6.27 Mn |
| 9 | Royalty Pharma | 27.25 Bn | 26.41 Bn | - | - |
| 10 | enGene Therapeutics | 124.81 Mn | 124.81 Mn | - | 2.29 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | 2.29 Mn |
| Jan 31, 2026 | 2.32 Mn |
| Oct 31, 2025 | 2.01 Mn |
| Jul 31, 2025 | 1.53 Mn |
| Apr 30, 2025 | 431,000.00 |
| Jan 31, 2025 | 416,000.00 |
| Oct 31, 2024 | 423,000.00 |
| Jul 31, 2024 | 422,000.00 |
| Apr 30, 2024 | 421,000.00 |
| Jan 31, 2024 | 393,000.00 |